Privia Health Group (NASDAQ:PRVA) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Privia Health Group (NASDAQ:PRVA) released its quarterly earnings results on Thursday. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.08 by $0.11, FiscalAI reports. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The business had revenue of $603.85 million during the quarter, compared to analyst estimates of $560.99 million. During the same period last year, the business posted $0.22 earnings per share. The company’s quarterly revenue was up 25.8% on a year-over-year basis.

Here are the key takeaways from Privia Health Group’s conference call:

• Provider and attribution growth: Implemented providers reached 5,535 (+13.6% YoY) and attributed lives hit 1.6M (+26.5% YoY), driving practice collections up 14.6% to $914.8M and providing visible revenue runway for 2026.
• Profitability expansion: Adjusted EBITDA rose 36.3% to $36.7M with EBITDA representing 28.5% of care margin (up 290 bps), and management expects ~20% EBITDA growth at the midpoint of guidance with ~80% conversion to free cash flow.
• Strong balance sheet and reiterated guidance: Ended Q1 with $419.5M cash and no debt, maintained full-year 2026 guidance (raising only attributed-lives range), and signaled capacity to fund organic growth and disciplined M&A.
• M&A and integration progress: The Evolent ACO assets are reported ahead of integration schedule, management says the business-development pipeline is robust and will be used to expand Privia’s multi-state footprint.
• Technology and AI focus: New CTO hire and a push to deploy generative AI across enterprise, care-center, and care-delivery workflows are expected to boost productivity and help push margins toward the high end of long-term targets.

Privia Health Group Stock Down 3.7%

Privia Health Group stock traded down $0.90 during midday trading on Friday, reaching $23.10. The company’s stock had a trading volume of 1,080,445 shares, compared to its average volume of 972,100. Privia Health Group has a fifty-two week low of $18.77 and a fifty-two week high of $26.51. The company has a market cap of $2.90 billion, a P/E ratio of 144.35, a P/E/G ratio of 1.50 and a beta of 0.96. The business has a 50-day simple moving average of $22.73 and a 200-day simple moving average of $23.34.

Insider Transactions at Privia Health Group

In other news, CEO Parth Mehrotra sold 26,509 shares of Privia Health Group stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $22.11, for a total transaction of $586,113.99. Following the sale, the chief executive officer owned 555,443 shares in the company, valued at approximately $12,280,844.73. The trade was a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David Mountcastle sold 1,206 shares of Privia Health Group stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $25.00, for a total value of $30,150.00. Following the sale, the chief financial officer owned 214,847 shares in the company, valued at $5,371,175. This trade represents a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 274,255 shares of company stock worth $6,299,092. Corporate insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Privia Health Group

Institutional investors have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC increased its position in Privia Health Group by 579.8% in the 4th quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock valued at $38,000 after acquiring an additional 1,351 shares during the period. Canada Pension Plan Investment Board boosted its holdings in Privia Health Group by 48.0% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after purchasing an additional 1,200 shares in the last quarter. Kestra Advisory Services LLC purchased a new stake in Privia Health Group in the 4th quarter valued at approximately $93,000. Raymond James Financial Inc. purchased a new stake in Privia Health Group in the 2nd quarter valued at approximately $113,000. Finally, Acadian Asset Management LLC purchased a new stake in Privia Health Group in the 1st quarter valued at approximately $154,000. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on PRVA. Truist Financial raised their price target on Privia Health Group from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Piper Sandler restated an “overweight” rating and set a $36.00 price target on shares of Privia Health Group in a research report on Thursday, February 26th. Barclays raised their price target on Privia Health Group from $23.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 25th. Citigroup decreased their target price on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Finally, Canaccord Genuity Group decreased their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a report on Friday. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.23.

More Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Privia Health reported first-quarter results that beat revenue expectations, with sales of $603.85 million versus the $560.99 million estimate, and EPS of $0.19 versus $0.08 expected. The company also said revenue rose 25.8% year over year, and it reiterated full-year 2026 guidance. Article Title
• Positive Sentiment: The company’s updated 2026 outlook calls for revenue of $2.4 billion to $2.5 billion, which is in line with or slightly above market expectations and supports the case for continued growth. Article Title
• Neutral Sentiment: Investors are also parsing the Q1 2026 earnings call transcript and related earnings coverage for management commentary on margins, utilization trends, and the path to hitting full-year targets. Article Title
• Negative Sentiment: Two insider-selling reports may be weighing on sentiment: the CFO sold about $179,690 of stock and a director sold about $427,229 of stock, which can signal caution even when fundamentals are improving. Article Title Article Title

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.